Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer

European Urology

Volumn 58, Issue 3, 2010, Pages 418-426

  Wang, Chunyang ^a,b,d   Tao, Weiyang ^c   Wang, Youdong ^a   Bikow, Jennifer ^a,d   Lu, Bingxin ^b   Keating, Armand ^d   Verma, Subodh ^a   Parker, Thomas G ^a   Han, Ruifa ^b   Wen, Xiao Yan ^a,b,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e McLaughlin Centre for Molecular Medicine   (Canada)

Author keywords

Angiogenesis inhibitors; Chemical genetics; Prostatic neoplasms; Rosuvastatin; Zebrafish

Indexed keywords

ANTINEOPLASTIC AGENT; ARISTOLOCHIC ACID; COMPACTIN; DIHYDROMUNDULETONE; ISOROTENONE; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHEMICAL GENETICS; DRUG EFFICACY; ENDOTHELIUM CELL; GENETIC SCREENING; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROBENZENES; HUMANS; MALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PYRIMIDINES; SULFONAMIDES; TUMOR CELLS, CULTURED; ZEBRAFISH;

EID: 77955513656     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.05.024     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics 2008 CA Cancer J Clin 58 2008 71 96
2. Y. Li, and P.J. Cozzi Angiogenesis as a strategic target for prostate cancer therapy Med Res Rev 30 2009 23 66
3. J.B. Aragon-Ching, and W.L. Dahut The role of angiogenesis inhibitors in prostate cancer Cancer J 14 2008 20 25
4. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286 (Pubitemid 46505878)
5. S. Taylor, and J. Folkman Protamine is an inhibitor of angiogenesis Nature 297 1982 307 312
6. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
7. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr., M. Feinsod, D.R. Guyer VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
8. R.S. Lokey Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia Curr Opin Chem Biol 7 2003 91 96
9. L.I. Zon, and R.T. Peterson In vivo drug discovery in the zebrafish Nat Rev Drug Discov 4 2005 35 44
10. G.N. Wheeler, and A.W. Brändli Simple vertebrate models for chemical genetics and drug discovery screens: lessons from zebrafish and Xenopus Dev Dyn 238 2009 1287 1308
11. T.C. Tran, B. Sneed, and J. Haider Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish Cancer Res 67 2007 11386 11392
12. G.N. Serbedzija, E. Flynn, and C.E. Willett Zebrafish angiogenesis: a new model for drug screening Angiogenesis 3 1999 353 359
13. S. Isogai, M. Horiguchi, and B.M. Weinstein The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development Dev Biol 230 2001 278 301
14. S.W. Jin, W. Herzog, and M.M. Santoro A transgene-assisted genetic screen identifies essential regulators of vascular development in vertebrate embryos Dev Biol. 307 2007 29 42
15. S. Trudel, A.K. Stewart, and Z. Li The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan Clin Cancer Res 13 2007 621 629
16. N. Weidner, J.P. Semple, W.R. Welch, and J. Folkman Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma N Engl J Med 324 1991 1 8
17. P.G. Kluetz, W.D. Figg, and W.L. Dahut Angiogenesis inhibitors in the treatment of prostate cancer Expert Opin Pharmacother 11 2010 233 247
18. J. Lee, K.H. Jung, and Y.S. Park Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study Cancer Chemother Pharmacol 64 2009 657 663
19. W. Kim, J.H. Yoon, and J.R. Kim Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma Cancer Chemother Pharmacol 64 2009 497 507
20. N. Fang, and J.E. Casida Anticancer action of cubé insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities Proc Natl Acad Sci U S A 95 1998 3380 3384
21. S.H. Oh, J.K. Woo, and Q. Jin Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha Int J Cancer 122 2008 5 14
22. A.P. Grollman, S. Shibutani, and M. Moriya Aristolochic acid and the etiology of endemic (Balkan) nephropathy Proc Natl Acad Sci U S A 104 2007 12129 12134
23. K. Gauthaman, C.Y. Fong, and A. Bongso Statins, stem cells, and cancer J Cell Biochem 106 2009 975 983
24. Y. Kureishi, Z. Luo, and I. Shiojima The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004 1010
25. M. Weis, C. Heeschen, A.J. Glassford, and J.P. Cooke Statins have biphasic effects on angiogenesis Circulation 105 2002 739 745
26. C. Urbich, E. Dernbach, A.M. Zeiher, and S. Dimmeler Double-edged role of statins in angiogenesis signaling Circ Res 90 2002 737 744
27. R.J. Hamilton, and S.J. Freedland Review of recent evidence in support of a role for statins in the prevention of prostate cancer Curr Opin Urol 18 2008 333 339
28. T.J. Murtola, T. Visakorpi, J. Lahtela, H. Syvälä, and TLj. Tammela Statins and prostate cancer prevention: where we are now, and future directions Nat Clin Pract Urol 5 2008 376 387
29. A.E. Semenova, I.V. Sergienko, and V.P. Masenko The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients Acta Cardiol 64 2009 405 409
30. H. Gbelcová, M. Lenícek, and J. Zelenka Differences in antitumor effects of various statins on human pancreatic cancer Int J Cancer 122 2008 1214 1221